multiepitope TARP-pulsed autologous dendritic cell vaccine

A cell-based cancer vaccine comprised of autologous dendritic cells pulsed with multiple antigenic peptides derived from T-cell receptor gamma-chain alternate reading frame protein (TARP), with potential immunostimulatory and antineoplastic activities. Upon intradermal administration, multi-epitope (ME) TARP-pulsed autologous dendritic cell vaccine may stimulate anti-tumor cytotoxic T-lymphocyte (CTL) and antibody responses against TARP-expressing cancer cells, resulting in tumor cell lysis. The highly immunogenic nuclear protein TARP is expressed in a variety of cancer cell types.